Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Ovidiu Chioncel, Beth Davison, Marianna Adamo, Laura E Antohi, Mattia Arrigo, Marianela Barros, Jan Biegus, Kamilė Čerlinskaitė-Bajorė, Jelena Celutkiene, Alain Cohen-Solal, Albertino Damasceno, Rafael Diaz, Christopher Edwards, Gerasimos Filippatos, Antoine Kimmoun, Carolyn S P Lam, Marco Metra, Maria Novosadova, Matteo Pagnesi, Peter S Pang, Piotr Ponikowski, Razvan I Radu, Hadiza Saidu, Karen Sliwa, Adriaan A Voors, Koji Takagi, Jozine M Ter Maaten, Daniela Tomasoni, Gad Cotter, Alexandre Mebazaa
AIMS: To assess the potential interaction between noncardiac comorbidities (NCCs) and the efficacy and safety of high intensity care (HIC) versus usual care (UC) in STRONG-HF trial, including stable patients with improved but still elevated NPs METHODS AND RESULTS: In the trial, 8 NCCs were reported: anemia, diabetes, renal dysfunction, severe liver disease, COPD/asthma, stroke/TIA, psychiatric/neurological disorders, and malignancies. Patients were classified by NCC number (0, 1, 2 and ≥3)...
September 20, 2023: European Journal of Heart Failure
#2
LETTER
Clément Delmas, Aurore Ughetto, Guillaume Lebreton, François Roubille
No abstract text is available yet for this article.
September 20, 2023: European Journal of Heart Failure
#3
JOURNAL ARTICLE
Daniel J Hammersley, Richard E Jones, Ruth Owen, Lukas Mach, Amrit S Lota, Zohya Khalique, Antonio De Marvao, Emmanuel Androulakis, Suzan Hatipoglu, Ankur Gulati, Rohin K Reddy, Won Young Yoon, Suprateeka Talukder, Riya Shah, Resham Baruah, Kaushik Guha, Antonis Pantazis, A John Baksi, John Gregson, John G F Cleland, Upasana Tayal, Dudley J Pennell, James S Ware, Brian P Halliday, Sanjay K Prasad
AIMS: To characterise the phenotype, clinical outcomes and rate of disease progression in patients with early-stage non-ischaemic cardiomyopathy (early-NICM). METHODS AND RESULTS: We conducted a prospective observational cohort study of patients with early-NICM assessed by late-gadolinium-enhancement cardiovascular magnetic resonance. Cases were classified into the following subgroups: isolated left ventricular dilation (early-NICM H-/D+), non-dilated left ventricular cardiomyopathy (early-NICM H+/D-) or early dilated cardiomyopathy (early-NICM H+/D+)...
September 20, 2023: European Journal of Heart Failure
#4
JOURNAL ARTICLE
Antoni Bayes-Genis, Kieran F Doherty, Mark C Petrie, James L Januzzi, Christian Mueller, Lisa Andreson, Biykem Bozkurt, Javed Butler, Ovidiu Chioncel, John Gf Cleland, Ruxandra Christodorescu, Stefano Del Prato, Finn Gustafsson, Carolyn S P Lam, Brenda Moura, Rodica Pop-Busui, Petar Seferovic, Maurizio Volterrani, Muthiah Vaduganathan, Marco Metra, Giuseppe Rosano
Diagnosing heart failure is often difficult due to the nonspecific nature of the symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. This document from the Heart Failure Association examines the practical uses of NT-proBNP in various clinical scenarios. The concentrations of NT-proBNP vary according to the patient profile and the clinical scenario, therefore values should be interpreted with caution to ensure appropriate diagnosis...
September 15, 2023: European Journal of Heart Failure
#5
JOURNAL ARTICLE
Anna Feuerstein, Felix Schoenrath, Evgeny Belyavskiy, Jan Knierim, Tim Friede, Marius Placzek, Doris Bach, Elisabeth Pieske-Kraigher, Christoph Herrmann-Lingen, Ralf Westenfeld, Michael Roden, Meike Rybczynski, Nicolas Verheyen, Marcus Dörr, Stephan von Haehling, Stefan Störk, Martin Halle, Volkmar Falk, Burkert Pieske, Frank Edelmann
AIMS: Small studies and observations suggested that exercise training may improve peak oxygen consumption (peakVO2 ) in patients with advanced heart failure and left ventricular assist device (LVAD). We investigated whether in this patient group a supervised exercise training can improve exercise capacity. METHODS AND RESULTS: In this multicenter, prospective, randomized, controlled trial patients with stable heart failure and LVAD were randomly assigned (2:1) to 12 weeks of supervised exercise training or usual care, with 12 weeks of follow-up...
September 13, 2023: European Journal of Heart Failure
#6
JOURNAL ARTICLE
Piergiuseppe Agostoni, Francesca Romana Pluchinotta, Elisabetta Salvioni, Massimo Mapelli, Arianna Galotta, Alice Bonomi, Damiano Magrì, Enrico Perna, Stefania Paolillo, Ugo Corrà, Rosa Raimondo, Rocco Lagioia, Roberto Badagliacca, Pasquale Perrone Filardi, Anna Apostolo, Michele Senni, Annamaria Iorio, Michele Correale, Jeness Campodonico, Pietro Palermo, Mariantonietta Cicoira, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Mauro Contini, Beatrice Pezzuto, Gianfranco Sinagra, Gianfranco Parati, Gaia Cattadori, Cosimo Carriere, Marco Cittar, Maria Vittoria Matassini, Andrea Salzano, Antonio Cittadini, Marco Masè, Francesco Bandera, Maurizio Bussotti, Irene Mattavelli, Federica Re, Carlo Vignati, Carlo Lombardi, Angela B Scardovi, Susanna Sciomer, Andrea Passantino, Michele Emdin, Andrea Di Lenarda, Claudio Passino, Caterina Santolamazza, Federica Moscucci, Denise Zaffalon, Massimo Piepoli
AIMS: Improvement of left ventricular ejection fraction is a major goal of heart failure (HF) treatment. However, data on clinical characteristics, exercise performance and prognosis in HF patients who improved ejection fraction (HFimpEF) are scarce. The study aimed to determine whether HFimpEF patients have a distinct clinical phenotype, biology and prognosis than HF patients with persistently reduced ejection fraction (pHFrEF). METHODS AND RESULTS: 7948 patients enrolled in the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database were evaluated (median follow-up of 1490 days)...
September 13, 2023: European Journal of Heart Failure
#7
EDITORIAL
Matthew W Segar, Neil Keshvani, Ambarish Pandey
No abstract text is available yet for this article.
September 13, 2023: European Journal of Heart Failure
#8
JOURNAL ARTICLE
Richard E Jones, Daniel J Hammersley, Sean Zheng, Kathryn A McGurk, Antonio de Marvao, Pantazis I Theotokis, Ruth Owen, Upasana Tayal, Gillian Rea, Suzan Hatipoglu, Rachel J Buchan, Lukas Mach, Lara Curran, Amrit S Lota, François Simard, Rohin K Reddy, Suprateeka Talukder, Won Young Yoon, Ali Vazir, Dudley J Pennell, Declan P O'Regan, A John Baksi, Brian P Halliday, James S Ware, Sanjay K Prasad
AIMS: To examine the relevance of genetic and cardiovascular magnetic resonance (CMR) features of dilated cardiomyopathy (DCM) in individuals with coronary artery disease (CAD). METHODS AND RESULTS: This study includes 2 cohorts. First, individuals with CAD recruited into the UK Biobank (UKB) were evaluated. Second, patients with CAD referred to a tertiary centre for evaluation with late gadolinium enhancement (LGE)-CMR were recruited (London cohort); patients underwent genetic sequencing as part of the research protocol and long-term follow-up...
September 13, 2023: European Journal of Heart Failure
#9
EDITORIAL
Pietro Ameri, Muthiah Vaduganathan
No abstract text is available yet for this article.
September 13, 2023: European Journal of Heart Failure
#10
JOURNAL ARTICLE
Pascal M Burger, Gianluigi Savarese, Jasper Tromp, Carly Adamson, Pardeep S Jhund, Lina Benson, Camilla Hage, Wan Ting Tay, Scott D Solomon, Milton Packer, Xavier Rossello, John W McEvoy, Dirk De Bacquer, Adam Timmis, Panos Vardas, Ian M Graham, Emanuele Di Angelantonio, Frank L J Visseren, John J V McMurray, Carolyn S P Lam, Lars H Lund, Stefan Koudstaal, Jannick A N Dorresteijn, Arend Mosterd
AIMS: Although trials have proven the group-level effectiveness of various therapies for heart failure with reduced ejection fraction (HFrEF), important differences in absolute effectiveness exist between individuals. We developed and validated the LIFEtime-perspective for Heart Failure (LIFE-HF) model for the prediction of individual (lifetime) risk and treatment benefit in patients with HFrEF. METHODS AND RESULTS: Cox proportional hazards functions with age as the time scale were developed in the PARADIGM-HF and ATMOSPHERE trials (n = 15,415)...
September 10, 2023: European Journal of Heart Failure
#11
EDITORIAL
Charles F Sherrod, Nobuhiro Ikemura, John A Spertus
No abstract text is available yet for this article.
September 6, 2023: European Journal of Heart Failure
#12
JOURNAL ARTICLE
Marat Fudim, Frederik Dalgaard, Daniel J Friedman, William T Abraham, John G F Cleland, Anne B Curtis, Michael R Gold, Valentina Kutyifa, Cecilia Linde, Fatima Ali-Ahmed, Anthony Tang, Antonio Olivas-Martinez, Lurdes Y T Inoue, Sana M Al-Khatib, Gillian D Sanders
BACKGROUND: Patients with heart failure usually have several other medical conditions that might alter the effects of interventions. We investigated whether the burden of comorbidity modified the clinical response to cardiac resynchronization therapy (CRT). METHODS AND RESULTS: Original patient-level data from eight randomized trials exploring the effects of CRT versus no CRT were pooled (BLOCK HF, MIRACLE, MIRACLE-ICD, MIRACLE-ICD-II, RAFT, COMPANION, MADIT-CRT and REVERSE)...
September 6, 2023: European Journal of Heart Failure
#13
JOURNAL ARTICLE
Margriet Bogerd, Sanne Ten Berg, Elma J Peters, Alexander P J Vlaar, Annemarie E Engström, Luuk C Otterspoor, Christian Jung, Dirk Westermann, Janine Pöss, Holger Thiele, Benedikt Schrage, José P S Henriques
AIMS: This study aimed to give contemporary insight into the use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) in acute myocardial infarction-related cardiogenic shock (AMICS) and into associated outcomes, adverse events, and resource demands. METHODS AND RESULTS: This nationwide observational cohort study describes all AMICS patients treated with Impella (ABIOMED, Danvers, MA, USA) and/or VA-ECMO in 2020-2021. Impella and/or VA-ECMO were used in 20% of all AMICS cases (n = 4088)...
September 6, 2023: European Journal of Heart Failure
#14
EDITORIAL
Pieter Martens, Wilfried Mullens
No abstract text is available yet for this article.
September 6, 2023: European Journal of Heart Failure
#15
EDITORIAL
Benedikt N Beer, Benedikt Schrage
No abstract text is available yet for this article.
September 4, 2023: European Journal of Heart Failure
#16
EDITORIAL
Rajat Kalra
No abstract text is available yet for this article.
September 4, 2023: European Journal of Heart Failure
#17
JOURNAL ARTICLE
Amr Abdin, Stefan D Anker, Martin R Cowie, Gerasimos S Filippatos, Piotr Ponikowski, Luigi Tavazzi, Jakob Schöpe, Stefan Wagenpfeil, Michel Komajda, Michael Böhm
AIMS: A high resting heart rate (RHR) and low systolic blood pressure (SBP) are a risk factor and a risk indicator, respectively, for poor heart failure (HF) outcomes. This analysis evaluates the associations between baseline RHR and SBP with outcomes and treatment patterns in HF patients with reduced ejection fraction (HFrEF) in the QUALIFY international registry. METHODS AND RESULTS: Between September 2013 and December 2014, 7317 HFrEF patients with a previous HF hospitalization within 1-15 months were enrolled in the QUALIFY registry (Quality of Adherence to Guideline Recommendations for Life-Saving Treatment in Heart Failure Survey)...
September 4, 2023: European Journal of Heart Failure
#18
JOURNAL ARTICLE
Haran Yogasundaram, Yinggan Zheng, Eric Ly, Justin Ezekowitz, Piotr Ponikowski, Carolyn S P Lam, Christopher O'Connor, Robert O Blaustein, Lothar Roessig, Tracy Temple, Cynthia M Westerhout, Paul W Armstrong, Roopinder K Sandhu
AIMS: Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown. METHODS AND RESULTS: We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12-lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N-terminal pro-B-type natriuretic peptide, and index event...
September 1, 2023: European Journal of Heart Failure
#19
JOURNAL ARTICLE
Nicolò De Biase, Matteo Mazzola, Lavinia Del Punta, Valerio Di Fiore, Marco De Carlo, Cristina Giannini, Giulia Costa, Francesco Paneni, Alessandro Mengozzi, Lorenzo Nesti, Luna Gargani, Stefano Masi, Nicola Riccardo Pugliese
BACKGROUND: Degenerative aortic valve stenosis with preserved left ventricular ejection fraction (ASpEF) and heart failure with preserved left ventricular ejection fraction (HFpEF) display intriguing similarities. We designed this study to provide a non-invasive, comparative analysis of ASpEF versus HFpEF at rest and during exercise. METHODS AND RESULTS: We prospectively enrolled 148 patients with HFpEF and 150 patients with degenerative moderate-to-severe ASpEF, together with 66 age- and sex-matched healthy controls...
September 1, 2023: European Journal of Heart Failure
#20
EDITORIAL
Yogesh N V Reddy, Barry A Borlaug
No abstract text is available yet for this article.
September 1, 2023: European Journal of Heart Failure
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
